دورية أكاديمية
Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer.
| العنوان: | Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer. |
|---|---|
| المؤلفون: | Qian X; Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.; Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; National Innovation Center for Fundamental Research on Cancer Medicine, Hangzhou 310009, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou 310058, Zhejiang, China.; ZJU-Pujian Research & Development Center of Medical Artificial Intelligence for Hepatobiliary and Pancreatic Disease, Hangzhou 310058, Zhejiang, China., Yang H; MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, Zhejiang, China., Ye Z; MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, Zhejiang, China., Gao B; Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.; Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; National Innovation Center for Fundamental Research on Cancer Medicine, Hangzhou 310009, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou 310058, Zhejiang, China.; ZJU-Pujian Research & Development Center of Medical Artificial Intelligence for Hepatobiliary and Pancreatic Disease, Hangzhou 310058, Zhejiang, China., Qian Z; Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.; Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; National Innovation Center for Fundamental Research on Cancer Medicine, Hangzhou 310009, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou 310058, Zhejiang, China.; ZJU-Pujian Research & Development Center of Medical Artificial Intelligence for Hepatobiliary and Pancreatic Disease, Hangzhou 310058, Zhejiang, China., Ding Y; Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.; Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; National Innovation Center for Fundamental Research on Cancer Medicine, Hangzhou 310009, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou 310058, Zhejiang, China.; ZJU-Pujian Research & Development Center of Medical Artificial Intelligence for Hepatobiliary and Pancreatic Disease, Hangzhou 310058, Zhejiang, China., Mao Z; Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.; Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, Zhejiang, China., Du Y; Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.; Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; National Innovation Center for Fundamental Research on Cancer Medicine, Hangzhou 310009, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou 310058, Zhejiang, China.; ZJU-Pujian Research & Development Center of Medical Artificial Intelligence for Hepatobiliary and Pancreatic Disease, Hangzhou 310058, Zhejiang, China., Wang W; Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.; Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, Zhejiang, China.; National Innovation Center for Fundamental Research on Cancer Medicine, Hangzhou 310009, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou 310058, Zhejiang, China.; ZJU-Pujian Research & Development Center of Medical Artificial Intelligence for Hepatobiliary and Pancreatic Disease, Hangzhou 310058, Zhejiang, China. |
| المصدر: | ACS nano [ACS Nano] 2024 Jun 18; Vol. 18 (24), pp. 15864-15877. Date of Electronic Publication: 2024 Jun 03. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Chemical Society Country of Publication: United States NLM ID: 101313589 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-086X (Electronic) Linking ISSN: 19360851 NLM ISO Abbreviation: ACS Nano Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington D.C. : American Chemical Society |
| مواضيع طبية MeSH: | Triple Negative Breast Neoplasms*/immunology , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/pathology , Celecoxib*/pharmacology , Celecoxib*/chemistry , Celecoxib*/administration & dosage , Paclitaxel*/pharmacology , Paclitaxel*/chemistry , Immunogenic Cell Death*/drug effects, Animals ; Mice ; Humans ; Female ; Cell Line, Tumor ; Mice, Inbred BALB C ; Liposomes/chemistry |
| مستخلص: | Triple-negative breast cancer (TNBC) is a highly aggressive malignancy that lacks effective targeted therapies. Inducing immunogenic cell death (ICD) in tumor cells represents a promising strategy to enhance therapeutic efficacy by promoting antitumor immunity. Paclitaxel (PTX), a commonly used chemotherapy drug for TNBC, can induce ICD; however, the resulting immunogenicity is limited. Thus, there is an urgent need to explore strategies that improve the effectiveness of ICD in TNBC by incorporating immunoregulatory agents. This study investigated the potential of celecoxib (CXB) to enhance PTX-induced ICD by blocking the biosynthesis of PGE |
| فهرسة مساهمة: | Keywords: celecoxib; drug combination; immunogenic cell death; nanomedicine; triple-negative breast cancer |
| المشرفين على المادة: | JCX84Q7J1L (Celecoxib) P88XT4IS4D (Paclitaxel) 0 (Liposomes) |
| تواريخ الأحداث: | Date Created: 20240603 Date Completed: 20240618 Latest Revision: 20240618 |
| رمز التحديث: | 20240618 |
| DOI: | 10.1021/acsnano.4c02947 |
| PMID: | 38829727 |
| قاعدة البيانات: | MEDLINE |
Find this issue from the American Chemical Society | تدمد: | 1936-086X |
|---|---|
| DOI: | 10.1021/acsnano.4c02947 |